VoiceMed launches two new clinical studies to validate vocal biomarkers in COPD patients within a real-world, home environment. The goal is to collect longitudinal data, improve model accuracy, and demonstrate the value of continuous, remote respiratory monitoring.

VoiceMed reaches €1 million in total funding to accelerate clinical studies and market entry. The investment will support technology development, scientific validation, and early integrations with healthcare partners, strengthening its position in digital respiratory care.

VoiceMed and Chiesi collaborate on a pilot project to test vocal biomarkers in chronic respiratory diseases. Results highlight the potential of the technology for screening and monitoring, paving the way for integration into existing clinical workflows.